Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Global X Autonomous & Electric Vehicles — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Global X Autonomous & Electric Vehicles trades at $35.71. Which is the better fit depends on your goals.
| ACAD | DRIV | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $42.53 |
52-Week Low | $20.06 | $23.67 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DRIV trades at $37.63, up 2.42% today, but technical signals are bearish with moving averages indicating selling pressure. The stock faces industry headwinds from shifting consumer demand and geopolitical tensions affecting fuel prices. Recent news highlights competitive threats from Chinese EV makers and regulatory uncertainties in the U.S. market, while a dividend of $0.07 is scheduled for July 2026.
Outlook remains cautious due to bearish technicals and sector volatility. Investment opportunities lie in exposure to autonomous driving and EV growth, but risks include intense competition, regulatory changes, and macroeconomic pressures. Wall Street sentiment is mixed, reflecting the ETF's diversified tech and auto holdings amid evolving market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
